Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 1;23(23):15080.
doi: 10.3390/ijms232315080.

Mesenchymal Stem Cells and Psoriasis: Systematic Review

Federico Diotallevi  1 , Mariangela Di Vincenzo  2 , Emanuela Martina  1 , Giulia Radi  1 , Vincenzo Lariccia  3 , Annamaria Offidani  1 , Monia Orciani  2 , Anna Campanati  1
Affiliations

Mesenchymal Stem Cells and Psoriasis: Systematic Review

Federico Diotallevi et al. Int J Mol Sci. .

Abstract

Mesenchymal Stem Cells (MSCs) are multipotent non-hematopoietic stromal cells found in different body tissues such as bone marrow, adipose tissue, periosteum, Wharton's jelly, umbilical cord, blood, placenta, amniotic fluid, and skin. The biological behavior of MSCs depends mainly on their interaction with the microenvironment in which they are found, whose quality deeply influences the regenerative and immunomodulatory properties of these cells. Several studies confirm the interaction between MSCs and inflammatory microenvironment in the pathogenesis of psoriasis, designating MSCs as an important factor driving psoriasis development. This review aims to describe the most recent evidence on how the inflammatory microenvironment that characterizes psoriasis influences the homeostasis of MSCs and how they can be used to treat the disease.

Keywords: biologics; mesenchymal stem cells; microenvironment; psoriasis; small molecules; systemic treatments.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) on the interaction between MSCs and microenvironment in psoriasis [17].
Figure 2
Figure 2
Cross-talking between PsO-MSCs and PsO-KCs: High levels of pro-inflammatory cytokines secreted by MSCs induce KCs proliferation, shortening the epidermal turnover time through secretion of several cytokines including Epidermal Growth Factor (EGF). PsO-KCs co-cultured with control MSCs upregulates the expression of c-Myc, GLUT1, SCF, and EGF, resulting in enhanced metabolism and increased proliferation of MSCs, establishing a vicious cycle.
Figure 3
Figure 3
Effects of PsO-MSCs on the vascularization of psoriatic lesions: upregulation of GLUT1, HK2, OCR, ATP-linked respiration, glucose metabolism, VEGF, IGFBP-5, DEL-1 and angiopoietin-2 in dermal PsO-MSCs promotes immune activation, keratinocytes proliferation, and angiogenesis in inflamed skin.
Figure 4
Figure 4
Relationships between PsO-MSCs and immune cells: overexpression of CMKLR1, COL8A1, NRK, and SYTL2 in PsO-MSCs promotes proliferation, differentiation, and migration of healthy peripheral blood mononuclear cells (PBMCs), including lymphocytes, basophils, neutrophils, eosinophils ad monocytes, through the activation of Wnt signaling pathway.
See this image and copyright information in PMC

References

    1. Michalek I.M., Loring B., John S.M. A systematic review of worldwide epidemiology of psoriasis. J. Eur. Acad. Derm. Venereol. 2017;31:205–212. doi: 10.1111/jdv.13854. - DOI - PubMed
    1. Blackstone B., Patel R., Bewley A. Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician. Psoriasis. 2022;12:25–33. doi: 10.2147/PTT.S328447. - DOI - PMC - PubMed
    1. Armstrong A.W., Robertson A.D., Wu J., Schupp C., Lebwohl M.G. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: Findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149:1180–1185. doi: 10.1001/jamadermatol.2013.5264. - DOI - PubMed
    1. Gisondi P., Cazzaniga S., Chimenti S., Maccarone M., Picardo M., Girolomoni G., Naldi L. Psocare Study Group. Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry. Br. J. Dermatol. 2015;172:1613–1620. doi: 10.1111/bjd.13539. - DOI - PubMed
    1. Bardazzi F., Magnano M., Campanati A., Loconsole F., Carpentieri A., Potenza C., Bernardini N., Di Lernia V., Carrera C., Raone B., et al. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience. Acta Derm. Venereol. 2017;97:989–990. doi: 10.2340/00015555-2698. - DOI - PubMed

Publication types

LinkOut - more resources